The Journal of Heart and Lung Transplantation
Volume 27, Issue 4 , Pages 462-465 , April 2008

Regression of Pulmonary Lymphangioleiomyomatosis (PLAM)-associated Retroperitoneal Angiomyolipoma Post–Lung Transplantation With Rapamycin Treatment

  • Judith M. Morton, MBBS, FRACP

      Affiliations

    • Lung Transplant Service, Department of Allergy, Immunology and Respiratory Medicine, Monash University, The Alfred Hospital, Prahran, Victoria, Australia
    • Department of Medicine, Monash University, The Alfred Hospital, Prahran, Victoria, Australia.
    • Corresponding Author InformationReprint requests: Judith M. Morton, FRACP, Department of Respiratory and Sleep Medicine, Monash Medical Centre, 246 Clayton Rd, Clayton, Victoria 3168, Australia.
    • ,
  • Catriona McLean, MBBS, FRCPA

      Affiliations

    • Department of Anatomical Pathology, Monash University, The Alfred Hospital, Prahran, Victoria, Australia
    • ,
  • Stephen S. Booth, MB, ChB

      Affiliations

    • Department of Radiology, Monash University, The Alfred Hospital, Prahran, Victoria, Australia
    • ,
  • Gregory I. Snell, MBBS, FRACP

      Affiliations

    • Lung Transplant Service, Department of Allergy, Immunology and Respiratory Medicine, Monash University, The Alfred Hospital, Prahran, Victoria, Australia
    • Department of Medicine, Monash University, The Alfred Hospital, Prahran, Victoria, Australia.
    • ,
  • Helen M. Whitford, MBBS, FRACP

      Affiliations

    • Lung Transplant Service, Department of Allergy, Immunology and Respiratory Medicine, Monash University, The Alfred Hospital, Prahran, Victoria, Australia
    • Department of Medicine, Monash University, The Alfred Hospital, Prahran, Victoria, Australia.

Received 16 September 2007 ,Revised 27 December 2007 ,Accepted 2 January 2008.

References 

  1. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart–lung transplant report—2005. J Heart Lung Transplant. 2005;24:956–967
  2. Nine JS, Yousem SA, Paradis IL, Keenan R, Griffith BP. Lymphangioleiomyomatosis: recurrence after lung transplantation. J Heart Lung Transplant. 1994;13:714–719
  3. O’Brien JD, Lium JH, Parosa JF, et al. Lymphangiomyomatosis recurrence in the allograft after single-lung transplantation. Am J Respir Crit Care Med. 1995;151:2033–2036
  4. Boehler A. Lung transplantation for cystic lung diseases: lymphangioleiomyomatosis, histiocytosis X, and sarcoidosis. Semin Respir Crit Care Med. 2001;22:509–516
  5. Bittmann I, Dose TB, Muller C, et al. Lymphangioleiomyomatosis: recurrence after single lung transplantation. Hum Pathol. 1997;28:1420–1423
  6. Avila NA, Kelly JA, Chu SC, Dwyer AJ, Moss J. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology. 2000;216:147–153
  7. Smolarek TA, Wessner LL, McCormack FX, et al. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet. 1998;62:810–815
  8. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA. 2000;97:6085–6090
  9. Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med. 2001;164:1537–1540
  10. Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation (A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)). J Biol Chem. 2002;277:30958–30967
  11. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103:253–262
  12. El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet. 2003;361:1348–1349
  13. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation. 2001;72:1181–1193
  14. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 2002;62:5645–5650
  15. Kenerson H, Dundon TA, Yeung RS. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res. 2005;57:67–75
  16. Dervaux T, Caillard S, Meyer C, et al. Is sirolimus responsible for proteinuria?. Transplant Proc. 2005;37:2828–2829
  17. Ruiz JC, Diekmann F, Campistol JM, et al. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study. Transplant Proc. 2005;37:3833–3835
  18. McWilliams TJ, Levvey BJ, Russell PA, Milne DG, Snell GI. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant. 2003;22:210–213
  19. Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant. 2002;21:540–546
  20. Snell GI, Levvey BJ, Chin W, et al. Rescue therapy: a role for sirolimus in lung and heart transplant recipients. Transplant Proc. 2001;33:1084–1085
  21. Snell GI, Valentine VG, Vitulo P, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant. 2006;6:169–177
  22. Kovarik JM, Snell GI, Valentine V, et al. Everolimus in pulmonary transplantation: pharmacokinetics and exposure–response relationships. J Heart Lung Transplant. 2006;25:440–446
  23. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80:883–889
  24. Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation. 2005;80:749–758
  25. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection. J Heart Lung Transplant. 1996;15:1–15

PII: S1053-2498(08)00006-5

doi: 10.1016/j.healun.2008.01.005

The Journal of Heart and Lung Transplantation
Volume 27, Issue 4 , Pages 462-465 , April 2008

Article Tools

* Image Usage & Resolution